Costa Mesa, CA (PRWEB) September 04, 2013<br /><br />WCCT Global, a contract research organization headquartered in Southern California, welcomes Lada Smirnova to the executive team as Chief Financial Officer. This addition is due to the organic growth WCCT Global has undergone in recent years and in preparation of acquiring more companies. Prior to joining WCCT, Lada held VP. of Finance and Accounting position with a well known CRO with experience in clinical trials across multiple therapeutic areas, from regulatory submissions and clinical affairs to medical monitoring and drug storage and distribution.<br /><br />Prior to VP of Finance and accounting position, Lada held Director of Finance and Administration position with several high tech companies. In those roles Lada was responsible for short and long-range financial and business planning as well as directly responsible for day-to-day operations of finance, accounting, IT, human resources, customer service, warehouse, and facility management departments. Among other responsibilities Lada was a project leader on several software conversions involving redesigning the business process, successfully completed SOX compliance implementation, and had a leadership role in internally initiated successful company restructuring.<br /><br />More about WCCT Global<br />WCCT Global is a multi-site, full service global contract research organization (CRO) of outsourced early drug development and late phase services to the pharmaceutical, biotechnology and medical device industries. The WCCT Global vision, “With compassion for people, we strive for tomorrow’s therapies to be available today” truly exemplifies the focus and reason for our cutting edge work both in our clinics and throughout our operations. As a drug development partner, WCCT Global collaborates with domestic and foreign innovator companies who need regulatory, program management, data management and strategic consulting support, with an emphasis on overseeing and executing trials in special disease populations, pediatric populations, ethno-bridging, and cardiac safety. WCCT has extensive experience with healthy volunteer studies including First-in-Human (FIH), as well as specific therapeutic expertise in Allergy, Asthma, HCV, Ophthalmology, Oncology, Renal, and Vaccines. 